he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:癫痫猝死:凶手是谁?
下一页:癫痫患儿死亡者简析
- 2022-04-202013年国际抗癫痫联合会抗癫痫止痛使用指南
- 2022-04-04FDA批准Aptiom用于治疗患者癫痫发作
- 2022-02-28后天早期癫痫病症状能疗程吗
- 2021-11-03小儿癫痫病症状主要有哪些?
- 上海率先探索异地就医门诊费直接结算
- 控制癫痫患者再次抽搐,不包括可选药物?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 北京癫痫手术费用
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- UCB的Vimpat癫痫新适应症在美国获批
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- FDA批准Aptiom用于治疗患者癫痫发作
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 综述:癫痫持续状态诊治最新进展
- 不注意这些问题,吃多少药都没用!
- Medpage Today:不同类型的抗癫痫药物更有利
- 抗癫痫药物预防新发癫痫:任重而道远
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 什么是治疗癫痫 癫痫有这些偏方?
- 三庚酸酯可治疗1型转运体缺陷综合征
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 癫痫的治疗方法 中医拔罐治疗癫痫的小方法(2)
- 癫痫治疗障碍仍难以克服
- 2016AAN:神经专家发表了有前途的专业见解
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 儿童癫痫的早期症状 癫痫的原因
- 心率多少正常 如何保持正常心率不变
- NeuroImage:纤维球成像可用于癫痫的进展
- 常见的癫痫病因有哪些?
- 癫痫患者手术评估新型工具
- 预测癫痫患者再入院风险
- 第四届全国临床脑电图实用系统地和实践操作培训班
- 现代癫痫病的症状都有什么
- 的人会能治癫痫病吗
- 如何能协助癫痫病人更好融入社会
- 临床如何诊断确实患有轻度癫痫
- 月经性发作患者孕期发作控制更佳
- 睡觉时抽搐回事癫痫病?
- 大脑或依赖于两种短时记忆系统
- 第三届国内脑电图规范阅图和临床实践提高班
- 小儿癫痫病要怎么治疗法呢
- 治疗癫痫病的最佳方法有如何能治好
- 忧郁症只是睡不好而已吗?
- 世界中风日 | 科学防治 规范诊疗 告别中风